High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints

Isavuconazole exposure–response relationships have been studied with a focus on total rather than unbound exposure, assuming a constant unbound fraction of 1%. We observed a median (range) unbound fraction of 1.59% (0.42–5.30%) in patients. This highly variable protein binding asks for re-evaluation...

Descripción completa

Detalles Bibliográficos
Autores principales: Jansen, Anouk M. E., ter Heine, Rob, Verweij, Paul E., Brüggemann, Roger J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684614/
https://www.ncbi.nlm.nih.gov/pubmed/37819504
http://dx.doi.org/10.1007/s40262-023-01311-w
_version_ 1785151442124800000
author Jansen, Anouk M. E.
ter Heine, Rob
Verweij, Paul E.
Brüggemann, Roger J. M.
author_facet Jansen, Anouk M. E.
ter Heine, Rob
Verweij, Paul E.
Brüggemann, Roger J. M.
author_sort Jansen, Anouk M. E.
collection PubMed
description Isavuconazole exposure–response relationships have been studied with a focus on total rather than unbound exposure, assuming a constant unbound fraction of 1%. We observed a median (range) unbound fraction of 1.59% (0.42–5.30%) in patients. This highly variable protein binding asks for re-evaluation of current pharmacokinetic and pharmacodynamic targets for isavuconazole.
format Online
Article
Text
id pubmed-10684614
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-106846142023-11-30 High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints Jansen, Anouk M. E. ter Heine, Rob Verweij, Paul E. Brüggemann, Roger J. M. Clin Pharmacokinet Commentary Isavuconazole exposure–response relationships have been studied with a focus on total rather than unbound exposure, assuming a constant unbound fraction of 1%. We observed a median (range) unbound fraction of 1.59% (0.42–5.30%) in patients. This highly variable protein binding asks for re-evaluation of current pharmacokinetic and pharmacodynamic targets for isavuconazole. Springer International Publishing 2023-10-11 2023 /pmc/articles/PMC10684614/ /pubmed/37819504 http://dx.doi.org/10.1007/s40262-023-01311-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Commentary
Jansen, Anouk M. E.
ter Heine, Rob
Verweij, Paul E.
Brüggemann, Roger J. M.
High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints
title High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints
title_full High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints
title_fullStr High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints
title_full_unstemmed High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints
title_short High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints
title_sort high variability in isavuconazole unbound fraction in clinical practice: a call to reconsider pharmacokinetic/pharmacodynamic targets and breakpoints
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684614/
https://www.ncbi.nlm.nih.gov/pubmed/37819504
http://dx.doi.org/10.1007/s40262-023-01311-w
work_keys_str_mv AT jansenanoukme highvariabilityinisavuconazoleunboundfractioninclinicalpracticeacalltoreconsiderpharmacokineticpharmacodynamictargetsandbreakpoints
AT terheinerob highvariabilityinisavuconazoleunboundfractioninclinicalpracticeacalltoreconsiderpharmacokineticpharmacodynamictargetsandbreakpoints
AT verweijpaule highvariabilityinisavuconazoleunboundfractioninclinicalpracticeacalltoreconsiderpharmacokineticpharmacodynamictargetsandbreakpoints
AT bruggemannrogerjm highvariabilityinisavuconazoleunboundfractioninclinicalpracticeacalltoreconsiderpharmacokineticpharmacodynamictargetsandbreakpoints

Ejemplares similares